



Press release 2016-02-08

C-RAD receives first U.S. order for a proton therapy center

C-RAD secured an order for a Catalyst PT™ system from a major health group in the U.S. for its proton therapy treatment center in Phoenix, Arizona. The order has a value of 1.7 MSEK.

As part of its proton beam therapy program, this large clinical group – which operates dozens of hospitals and clinics in the U.S. – has built two treatment centers. The first site in Rochester, Minnesota opened in the summer of 2015 while the site in Phoenix is expected to open in the spring of 2016. The facility has four treatment rooms, which will be commissioned in 2016. Delivery and installation of the C-RAD system is expected to take place during the second quarter of 2016.

The site is equipped with a Hitachi Proton Therapy system, making it the first installation in a Hitachi facility for C-RAD.

According to “US Proton Therapy Market Outlook 2020”, a report by RNCOS, the United States will be home to 29 particle therapy centers by 2020. The market is expected to grow between 11 – 17% annually until 2030. The requirements for high precision during proton therapy treatments open up the potential for the C-RAD patient monitoring solution.

C-RAD has released a specific version of its Catalyst System for use in proton and particle therapy. Software and hardware are tailored for the application in this particular environment. The Catalyst™ and Sentinel™ systems offer the required technology to perform the high-end radiation therapy treatment techniques that are increasingly common in the U.S. With its dual solution C-RAD supports the whole 4D treatment chain from imaging to treatment delivery. Respiratory gated treatments are frequently used when the target volume is close to cardiac tissue or for special treatments in which the tumor position depends on the respiratory cycle.

“I am happy to announce this strategically important order from the US market,” says Tim Thurn, CEO of C-RAD. “As it’s the first of its kind in the U.S., this project will enjoy special attention. We are very excited to work with this major national healthcare and research group on such a prestigious project.”

About C-RAD

C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. Employees currently number 40. C-RAD’s business originates from research and development at Karolinska Institutet in Solna, Sweden. Sales of the company’s first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with Elekta (Sweden), Varian (USA) and IBA (Belgium). C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in



China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are being integrated. C-RAD AB is listed on NASDAQ Stockholm.

For more information on C-RAD, please visit www.c-rad.com

For further information:

Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

The above information is price-sensitive and must therefore be disclosed under the Securities Market Act (2007:528).

